• J W Eikelboom, S Kozek-Langenecker, A Exadaktylos, A Batorova, Z Boda, F Christory, I Gornik, G Kėkštas, A Kher, R Komadina, O Koval, G Mitic, T Novikova, E Pazvanska, S Ratobilska, J Sütt, A Winder, and D Zateyshchikov.
• Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
• Br J Anaesth. 2018 Apr 1; 120 (4): 645-656.

AbstractNon-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated-as any anticoagulant-with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

16 keywords...

hide…